相似文献
1
Targeting pan-essential genes in cancer: Challenges and opportunities.
Cancer Cell. 2021 Apr 12;39(4):466-479. doi: 10.1016/j.ccell.2020.12.008. Epub 2021 Jan 14.
2
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Future Oncol. 2015;11(2):279-93. doi: 10.2217/fon.14.198.
3
Progress and challenges towards targeted delivery of cancer therapeutics.
Nat Commun. 2018 Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y.
4
Potential Successes and Challenges of Targeted Cancer Therapies.
J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53). doi: 10.1093/jncimonographs/lgz008.
5
Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeutics.
J Natl Cancer Inst. 2024 Jul 1;116(7):1012-1018. doi: 10.1093/jnci/djae075.
6
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Ann Oncol. 2016 Feb;27(2):214-24. doi: 10.1093/annonc/mdv550. Epub 2015 Nov 16.
7
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Nat Commun. 2019 Dec 20;10(1):5817. doi: 10.1038/s41467-019-13805-y.
8
Targeted cancer therapies.
Chin J Cancer. 2011 Jan;30(1):1-4. doi: 10.5732/cjc.010.10553.
9
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0.
10
Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics.
Discov Med. 2016 Sep;22(120):157-166.
引用本文的文献
1
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.
Front Cell Dev Biol. 2025 Aug 6;13:1608480. doi: 10.3389/fcell.2025.1608480. eCollection 2025.
2
The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.
Nat Genet. 2025 Jul 4. doi: 10.1038/s41588-025-02222-1.
3
RBPMS2 can inhibit the NLRP3 / caspase-1 / GSDMD signaling pathway to resist pyroptosis in gastric cancer cells.
Sci Rep. 2025 Jul 1;15(1):21294. doi: 10.1038/s41598-025-01125-9.
4
Fungi and cancer: unveiling the complex role of fungal infections in tumor biology and therapeutic resistance.
Front Cell Infect Microbiol. 2025 Jun 10;15:1596688. doi: 10.3389/fcimb.2025.1596688. eCollection 2025.
5
A study on the prediction of targeted therapy efficacy in advanced lung adenocarcinoma patients with EGFR mutations using CT-based delta-radiomics model.
Front Med (Lausanne). 2025 May 30;12:1599206. doi: 10.3389/fmed.2025.1599206. eCollection 2025.
6
Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung adenocarcinoma.
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf266.
7
Targeting SNRPE to Induce Pyroptosis Enhances Antitumor Immunity in Breast Cancer.
Int J Med Sci. 2025 Apr 28;22(10):2419-2433. doi: 10.7150/ijms.109171. eCollection 2025.
8
MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens.
Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2425052122. doi: 10.1073/pnas.2425052122. Epub 2025 May 16.
9
Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug.
Ann Med Surg (Lond). 2025 Feb 28;87(3):1506-1528. doi: 10.1097/MS9.0000000000003043. eCollection 2025 Mar.
10
Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View.
Small Sci. 2022 Jun 3;2(7):2200024. doi: 10.1002/smsc.202200024. eCollection 2022 Jul.
本文引用的文献
1
Genomics-guided pre-clinical development of cancer therapies.
Nat Cancer. 2020 May;1(5):482-492. doi: 10.1038/s43018-020-0067-x. Epub 2020 May 22.
2
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
3
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.
Nat Commun. 2020 Sep 18;11(1):4687. doi: 10.1038/s41467-020-18377-w.
4
Optimization of AsCas12a for combinatorial genetic screens in human cells.
Nat Biotechnol. 2021 Jan;39(1):94-104. doi: 10.1038/s41587-020-0600-6. Epub 2020 Jul 13.
5
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
Cell. 2020 Jul 9;182(1):200-225.e35. doi: 10.1016/j.cell.2020.06.013.
6
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Nat Cancer. 2020 Feb;1(2):235-248. doi: 10.1038/s43018-019-0018-6. Epub 2020 Jan 20.
7
Functional Genomics for Cancer Drug Target Discovery.
Cancer Cell. 2020 Jul 13;38(1):31-43. doi: 10.1016/j.ccell.2020.04.006. Epub 2020 May 21.
8
Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities.
Nat Commun. 2020 May 20;11(1):2517. doi: 10.1038/s41467-020-16399-y.
9
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.
Cancer Cell. 2020 Apr 13;37(4):514-529. doi: 10.1016/j.ccell.2020.03.010.
10
Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform.
Nat Biotechnol. 2020 May;38(5):638-648. doi: 10.1038/s41587-020-0437-z. Epub 2020 Mar 16.
Zotero 插件